Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice.

Stephan R KünzelLuise WinterMaximilian HoffmannTheresa A KantJessica ThielRomy Kronstein-WiedemannErik KlapprothKristina LorenzAli El-Armouche Susanne Kämmerer

Published in: Physiological reports (2023)

Our findings warrant further studies on mesalazine as a potential add-on therapy post-MI, as perivascular fibrosis development was successfully prevented.

Keyphrases

heart failure
left ventricular
emergency department
stem cells
drug induced
climate change